Claim being checked · Version 1 · Reviewed
“Cardiovascular trial results prove a universal longevity benefit.”
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
No dosing advice. This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Not established. The reviewed evidence does not establish this statement. This does not prove it can never be true.
Answer scope
This verdict checks the exact claim in the heading. It is not a universal grade for Liraglutide.
01 · Answer
Not established
LEADER tested a defined cardiovascular composite in a high-risk type 2 diabetes population, not lifespan extension in the general population.
- What kind of evidence this is
- Randomized human outcomes. This answer uses a study that assigned people to groups by chance and measured a health outcome.
- What this answer covers
- Adults with type 2 diabetes and high cardiovascular risk in LEADER. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
- Question type
- Longevity. What research does or does not show about living longer or staying healthy longer.
02 · Sources
Read the sources behind this answer
- Editorial review
- Internal editorial review recorded
- Source review
- Anthony Treviso · Founder and responsible editor
- Medical review status
- Not independently medically reviewed. Editorial source review does not replace medical review.